Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Walton · SciRah

Researcher profile · Semantic Scholar

M. Walton

Share profile

M. Walton — researcher profile on SciRah

h-index: 37
Works: 94
Citations: 5,131

Most-cited papers

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
T. Yap, M. Garrett, M. Walton, F. Raynaud +2 more
2008Current opinion in pharmacology (Print)565 citations
Semantic Scholar
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
U. Banerji, A. O'Donnell, M. Scurr, S. Pacey +11 more
2005Journal of Clinical Oncology505 citations Open access
Semantic Scholar
Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis.
M. Walton, D. Whysong, P. O'Connor, D. Hockenbery +2 more
1993Cancer Research298 citations
Semantic Scholar
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson, J. White, J. de Bono, A. O'Donnell +10 more
2006British Journal of Cancer272 citations Open access
Semantic Scholar
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone
P. Clarke, I. Hostein, U. Banerji, F. di Stefano +4 more
2000Oncogene211 citations
Semantic Scholar
A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
S. Pacey, R. Wilson, M. Walton, M. Eatock +12 more
2011Clinical Cancer Research199 citations Open access
Semantic Scholar
The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway
S. Whittaker, M. Walton, M. Garrett, P. Workman
2004Cancer Research187 citations Open access
Semantic Scholar
DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer
N. Kanu, M. Cerone, Gerald Goh, L. Zalmas +13 more
2016Genome Biology155 citations Open access
Semantic Scholar
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
A. Maloney, P. Clarke, S. Naaby-Hansen, R. Stein +17 more
2007Cancer Research145 citations Open access
Semantic Scholar
Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino , 17-Demethoxygeldanamycin in Human Ovarian Cancer
U. Banerji, M. Walton, F. Raynaud, R. Grimshaw +4 more
2005137 citations
Semantic Scholar
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
S. Pacey, M. Gore, D. Chao, U. Banerji +9 more
2012Investigational new drugs135 citations
Semantic Scholar
In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202
F. Raynaud, S. Whittaker, P. Fischer, S. Mcclue +11 more
2005Clinical Cancer Research135 citations Open access
Semantic Scholar
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells
N. Gaspar, S. Sharp, S. Pacey, Chris Jones +5 more
2009Cancer Research116 citations Open access
Semantic Scholar
CCT241533 is a potent and selective inhibitor of CHK2 which potentiates the cytotoxicity of PARP inhibitors
V. Anderson, M. Walton, Paul D. Eve, K. Boxall +7 more
2011Cancer Research107 citations Open access
Semantic Scholar
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Yuen-Li Chung, H. Troy, U. Banerji, L. Jackson +7 more
2003Journal of the National Cancer Institute104 citations
Semantic Scholar
The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
M. Walton, Paul J. Smith, P. Workman
1991Cancer Communications104 citations
Semantic Scholar
Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions.
P. Hoban, M. Walton, C. Robson, J. Godden +4 more
1990Cancer Research92 citations
Semantic Scholar
CCT244747 is a novel, potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
M. Walton, Paul D. Eve, A. Hayes, M. Valenti +16 more
2012Clinical Cancer Research91 citations Open access
Semantic Scholar
The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
M. Walton, Paul D. Eve, A. Hayes, M. Valenti +10 more
2010Molecular Cancer Therapeutics89 citations
Semantic Scholar
AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
T. Yap, M. Walton, Kyla M. Grimshaw, R. Te Poele +18 more
2012Clinical Cancer Research78 citations
Semantic Scholar
Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930
T. Yap, M. Walton, L. J. Hunter, M. Valenti +15 more
2010Molecular Cancer Therapeutics71 citations Open access
Semantic Scholar
Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
M. Walton, P. Workman
1990Biochemical Pharmacology65 citations
Semantic Scholar
Enzyme-Directed Bioreductive Drug Development
P. Workman, M. Walton
199065 citations
Semantic Scholar
DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?
P. Workman, M. Walton, G. Powis, John J. Schlager
1989British Journal of Cancer65 citations Open access
Semantic Scholar
The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis
S. Whittaker, R. Te Poele, Florence Chan, S. Linardopoulos +3 more
2007Cell Cycle64 citations Open access
Semantic Scholar
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
M. Walton, Paul D. Eve, A. Hayes, A. Henley +18 more
2015OncoTarget60 citations Open access
Semantic Scholar
An evaluation of the ability of pifithrin-α and -β to inhibit p53 function in two wild-type p53 human tumor cell lines
M. Walton, Stuart C. Wilson, I. Hardcastle, Amin Mirza +1 more
2005Molecular Cancer Therapeutics60 citations Open access
Semantic Scholar
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth
Kyla M. Grimshaw, L. J. Hunter, T. Yap, S. Heaton +11 more
2010Molecular Cancer Therapeutics58 citations Open access
Semantic Scholar
Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing
J. Reader, Thomas P. Matthews, Suki Klair, Kwai-Ming J. Cheung +24 more
2011Journal of Medicinal Chemistry56 citations Open access
Semantic Scholar
A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics.
J. Roberts, N. Bleehen, M. Walton, Paul Workman
1986British Journal of Radiology53 citations
Semantic Scholar
A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
J. Roberts, N. Bleehen, P. Workman, M. Walton
1984International Journal of Radiation Oncology, Biology, Physics47 citations
Semantic Scholar
CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells
Rebecca F. Rogers, M. Walton, D. Cherry, I. Collins +3 more
2020Cancer Research46 citations Open access
Semantic Scholar
Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival.
J. Renshaw, R. M. Orr, M. Walton, R. Te Poele +5 more
2004Molecular Cancer Therapeutics44 citations
Semantic Scholar
The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
M. Walton, N. Sugget, P. Workman
1992International Journal of Radiation Oncology, Biology, Physics43 citations Open access
Semantic Scholar
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models
U. Banerji, N. Sain, S. Sharp, M. Valenti +8 more
2008Cancer Chemotherapy and Pharmacology42 citations
Semantic Scholar
Identification of inhibitors of checkpoint kinase 1 through template screening.
Thomas P. Matthews, Suki Klair, S. Burns, K. Boxall +12 more
2009Journal of Medicinal Chemistry39 citations Open access
Semantic Scholar
Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
S. M. Bailey, N. Suggett, M. Walton, P. Workman
1992International Journal of Radiation Oncology, Biology, Physics38 citations Open access
Semantic Scholar
An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines.
M. Walton, Stuart C. Wilson, I. Hardcastle, Amin Mirza +1 more
2005Molecular Cancer Therapeutics37 citations
Semantic Scholar
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
James D. Osborne, Thomas P. Matthews, T. McHardy, Nicolas Proisy +23 more
2016Journal of Medicinal Chemistry34 citations Open access
Semantic Scholar
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Stuart C. Wilson, B. Atrash, C. Barlow, S. Eccles +15 more
2011Bioorganic & Medicinal Chemistry33 citations Open access
Semantic Scholar
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor
S. Whittaker, C. Barlow, Mathew P. Martin, C. Mancusi +16 more
2018Molecular Oncology31 citations Open access
Semantic Scholar
Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
M. Walton, Paul Workman
1993Journal of Pharmacology and Experimental Therapeutics31 citations
Semantic Scholar
A phase I study of the combination of benznidazole and CCNU in man.
J. Roberts, N. Bleehen, F. Y. Lee, P. Workman +1 more
1984International Journal of Radiation Oncology, Biology, Physics31 citations
Semantic Scholar
Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors
M. Lainchbury, Thomas P. Matthews, T. McHardy, K. Boxall +12 more
2012Journal of Medicinal Chemistry30 citations Open access
Semantic Scholar
Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells
G.-C. Huang, S. Hobbs, M. Walton, Rj Epstein
2002British Journal of Cancer29 citations Open access
Semantic Scholar
The contemporary drug development process: advances and challenges in preclinical and clinical development.
M. Garrett, M. Walton, E. Mcdonald, I. Judson +1 more
2003Progress in cell cycle research28 citations
Semantic Scholar
Assays for HSP90 and inhibitors.
W. Aherne, A. Maloney, C. Prodromou, M. Rowlands +6 more
2003Methods in Molecular Medicine27 citations Open access
Semantic Scholar
Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120
M. Walton, P. Goddard, L. Kèlland, D. E. Thurston +1 more
1996Cancer Chemotherapy and Pharmacology24 citations
Semantic Scholar
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease
Giampiero Colombano, J. Caldwell, Thomas P. Matthews, C. Bhatia +17 more
2019Journal of Medicinal Chemistry23 citations Open access
Semantic Scholar
The Cyclin-dependent Kinase Inhibitor CYC 202 ( R-Roscovitine ) Inhibits Retinoblastoma Protein Phosphorylation , Causes Loss of Cyclin D 1 , and Activates the Mitogen-activated Protein Kinase Pathway
S. Whittaker, M. Walton, M. Garrett, P. Workman
200418 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Workman×35
Invite
P. Workman — researcher profile on SciRah
M. Garrett×19
Invite
M. Garrett — researcher profile on SciRah
F. Raynaud×17
Invite
F. Raynaud — researcher profile on SciRah
S. Eccles×12
Invite
S. Eccles — researcher profile on SciRah

×11

Invite

M. Valenti — researcher profile on SciRah

Invite

I. Collins — researcher profile on SciRah

Invite

I. Judson — researcher profile on SciRah

Invite

K. Boxall — researcher profile on SciRah

Invite

U. Banerji — researcher profile on SciRah

Invite

Paul D. Eve — researcher profile on SciRah

A. K. de Haven Brandon×8

Invite

A. K. de Haven Brandon — researcher profile on SciRah

Invite

A. Hayes — researcher profile on SciRah